請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/53836
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 沈麗娟 | |
dc.contributor.author | Tzyy-Harn Yeh | en |
dc.contributor.author | 葉紫涵 | zh_TW |
dc.date.accessioned | 2021-06-16T02:30:57Z | - |
dc.date.available | 2020-09-24 | |
dc.date.copyright | 2015-09-24 | |
dc.date.issued | 2015 | |
dc.date.submitted | 2015-07-30 | |
dc.identifier.citation | [1] Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN. Overview of resistance to systemic therapy in patients with breast cancer. Advances in experimental medicine and biology. 2007;608:1-22. [2] Du JZ, Mao CQ, Yuan YY, Yang XZ, Wang J. Tumor extracellular acidity-activated nanoparticles as drug delivery systems for enhanced cancer therapy. Biotechnology advances. 2014;32:789-803. [3] Jain A, Jain A, Gulbake A, Shilpi S, Hurkat P, Jain SK. Peptide and protein delivery using new drug delivery systems. Critical reviews in therapeutic drug carrier systems. 2013;30:293-329. [4] Kizaka-Kondoh S, Inoue M, Harada H, Hiraoka M. Tumor hypoxia: a target for selective cancer therapy. Cancer Sci. 2003;94:1021-8. [5] Roth TF, Porter KR. Yolk Protein Uptake in the Oocyte of the Mosquito Aedes Aegypti. L. The Journal of cell biology. 1964;20:313-32. [6] Semenza GL. Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends in pharmacological sciences. 2012;33:207-14. [7] Brahimi-Horn MC, Pouyssegur J. Hypoxia in cancer cell metabolism and pH regulation. Essays in biochemistry. 2007;43:165-78. [8] Comerford KM, Wallace TJ, Karhausen J, Louis NA, Montalto MC, Colgan SP. Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res. 2002;62:3387-94. [9] Mayer A, Vaupel P. Hypoxia, lactate accumulation, and acidosis: siblings or accomplices driving tumor progression and resistance to therapy? Oxygen Transport to Tissue XXXV: Springer; 2013. p. 203-9. [10] Yoon C, Lee HJ, Park DJ, Lee YJ, Tap WD, Eisinger-Mathason TS, et al. Hypoxia-activated chemotherapeutic TH-302 enhances the effects of VEGF-A inhibition and radiation on sarcomas. Br J Cancer. 2015. [11] Kagiya G, Ogawa R, Choudhuri R, Cook JA, Hatashita M, Tanaka Y, et al. Selective enhancement of hypoxic cell killing by tempol-regulated suicide gene expression. Oncol Rep. 2015. [12] Doleschel D, Rix A, Arns S, Palmowski K, Gremse F, Merkle R, et al. Erythropoietin improves the accumulation and therapeutic effects of Carboplatin by enhancing tumor vascularization and perfusion. Theranostics. 2015;5:905-18. [13] Wouters BG, Weppler SA, Koritzinsky M, Landuyt W, Nuyts S, Theys J, et al. Hypoxia as a target for combined modality treatments. European journal of cancer. 2002;38:240-57. [14] Zheng R, Yao Q, Xie G, Du S, Ren C, Wang Y, et al. TAT-ODD-p53 enhances the radiosensitivity of hypoxic breast cancer cells by inhibiting Parkin-mediated mitophagy. Oncotarget. 2015. [15] Splith K, Bergmann R, Pietzsch J, Neundorf I. Specific targeting of hypoxic tumor tissue with nitroimidazole-peptide conjugates. ChemMedChem. 2012;7:57-61. [16] Ibraheem D, Elaissari A, Fessi H. Administration strategies for proteins and peptides. Int J Pharm. 2014;477:578-89. [17] Carter PJ. Introduction to current and future protein therapeutics: a protein engineering perspective. Experimental cell research. 2011;317:1261-9. [18] Salemme FR. Structure and function of cytochromes c. Annual review of biochemistry. 1977;46:299-329. [19] Green DR, Reed JC. Mitochondria and apoptosis. Science. 1998;281:1309-12. [20] Cao X, Bennett RL, May WS. c-Myc and caspase-2 are involved in activating Bax during cytotoxic drug-induced apoptosis. J Biol Chem. 2008;283:14490-6. [21] Jurgensmeier JM, Xie Z, Deveraux Q, Ellerby L, Bredesen D, Reed JC. Bax directly induces release of cytochrome c from isolated mitochondria. Proc Natl Acad Sci U S A. 1998;95:4997-5002. [22] Rosse T, Olivier R, Monney L, Rager M, Conus S, Fellay I, et al. Bcl-2 prolongs cell survival after Bax-induced release of cytochrome c. Nature. 1998;391:496-9. [23] Tait SW, Green DR. Mitochondria and cell death: outer membrane permeabilization and beyond. Nature reviews Molecular cell biology. 2010;11:621-32. [24] Danial NN, Korsmeyer SJ. Cell death: critical control points. Cell. 2004;116:205-19. [25] Dubrez-Daloz L, Dupoux A, Cartier J. IAPs: more than just inhibitors of apoptosis proteins. Cell cycle. 2008;7:1036-46. [26] Santra S, Kaittanis C, Perez JM. Cytochrome C encapsulating theranostic nanoparticles: a novel bifunctional system for targeted delivery of therapeutic membrane-impermeable proteins to tumors and imaging of cancer therapy. Mol Pharm. 2010;7:1209-22. [27] Kenien R, Shen WC, Zaro JL. Vesicle-to-cytosol transport of disulfide-linked cargo mediated by an amphipathic cell-penetrating peptide. Journal of drug targeting. 2012;20:793-800. [28] Kim SK, Foote MB, Huang L. The targeted intracellular delivery of cytochrome C protein to tumors using lipid-apolipoprotein nanoparticles. Biomaterials. 2012;33:3959-66. [29] Shen LJ, Shen WC. Drug evaluation: ADI-PEG-20--a PEGylated arginine deiminase for arginine-auxotrophic cancers. Current opinion in molecular therapeutics. 2006;8:240-8. [30] Ott PA, Carvajal RD, Pandit-Taskar N, Jungbluth AA, Hoffman EW, Wu BW, et al. Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma. Investigational new drugs. 2013;31:425-34. [31] Yang TS, Lu SN, Chao Y, Sheen IS, Lin CC, Wang TE, et al. A randomised phase II study of pegylated arginine deiminase (ADI-PEG 20) in Asian advanced hepatocellular carcinoma patients. British journal of cancer. 2010;103:954-60. [32] Glazer ES, Piccirillo M, Albino V, Di Giacomo R, Palaia R, Mastro AA, et al. Phase II study of pegylated arginine deiminase for nonresectable and metastatic hepatocellular carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010;28:2220-6. [33] Yardley DA. nab-Paclitaxel mechanisms of action and delivery. J Control Release. 2013;170:365-72. [34] Shen LJ, Beloussow K, Shen WC. Modulation of arginine metabolic pathways as the potential anti-tumor mechanism of recombinant arginine deiminase. Cancer Lett. 2006;231:30-5. [35] Feun L, Savaraj N. Pegylated arginine deiminase: a novel anticancer enzyme agent. Expert opinion on investigational drugs. 2006;15:815-22. [36] Lambeir AM, Rea D, Fulop V, Kumagai Y, Augustyns K, de Meester I, et al. Exploration of the active site of dipeptidyl peptidase IV from Porphyromonas gingivalis. Comparison with the human enzyme. Advances in experimental medicine and biology. 2003;524:29-35. [37] Wu FL, Yeh TH, Chen YL, Chiu YC, Cheng JC, Wei MF, et al. Intracellular delivery of recombinant arginine deiminase (rADI) by heparin-binding hemagglutinin adhesion peptide restores sensitivity in rADI-resistant cancer cells. Mol Pharm. 2014;11:2777-86. [38] Takakura Y, Hashida M. Macromolecular carrier systems for targeted drug delivery: pharmacokinetic considerations on biodistribution. Pharm Res. 1996;13:820-31. [39] Kawakami S, Hashida M. Glycosylation-mediated targeting of carriers. J Control Release. 2014;190:542-55. [40] Furuhata M, Kawakami H, Toma K, Hattori Y, Maitani Y. Intracellular delivery of proteins in complexes with oligoarginine-modified liposomes and the effect of oligoarginine length. Bioconjug Chem. 2006;17:935-42. [41] Yoon HY, Lee SH, Cho SW, Lee JE, Yoon CS, Park J, et al. TAT-mediated delivery of human glutamate dehydrogenase into PC12 cells. Neurochemistry international. 2002;41:37-42. [42] Alcala-Alcala S, Urban-Morlan Z, Aguilar-Rosas I, Quintanar-Guerrero D. A biodegradable polymeric system for peptide-protein delivery assembled with porous microspheres and nanoparticles, using an adsorption/infiltration process. Int J Nanomedicine. 2013;8:2141-51. [43] Bareford LM, Swaan PW. Endocytic mechanisms for targeted drug delivery. Adv Drug Deliv Rev. 2007;59:748-58. [44] Fonseca SB, Pereira MP, Kelley SO. Recent advances in the use of cell-penetrating peptides for medical and biological applications. Adv Drug Deliv Rev. 2009;61:953-64. [45] Elzoghby AO, Samy WM, Elgindy NA. Albumin-based nanoparticles as potential controlled release drug delivery systems. J Control Release. 2012;157:168-82. [46] Kratz F, Beyer U. Serum proteins as drug carriers of anticancer agents: a review. Drug Deliv. 1998;5:281-99. [47] Kratz F. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J Control Release. 2008;132:171-83. [48] Desai N. Challenges in development of nanoparticle-based therapeutics. The AAPS journal. 2012;14:282-95. [49] Lee ES, Shin HJ, Na K, Bae YH. Poly(L-histidine)-PEG block copolymer micelles and pH-induced destabilization. J Control Release. 2003;90:363-74. [50] Park IK, Park YH, Shin BA, Choi ES, Kim YR, Akaike T, et al. Galactosylated chitosan-graft-dextran as hepatocyte-targeting DNA carrier. J Control Release. 2000;69:97-108. [51] Gu FX, Karnik R, Wang AZ, Alexis F, Levy-Nissenbaum E, Hong S, et al. Targeted nanoparticles for cancer therapy. Nano today. 2007;2:14-21. [52] Fang J, Sawa T, Maeda H. Factors and mechanism of 'EPR' effect and the enhanced antitumor effects of macromolecular drugs including SMANCS. Advances in experimental medicine and biology. 2003;519:29-49. [53] Song G, Petschauer JS, Madden AJ, Zamboni WC. Nanoparticles and the mononuclear phagocyte system: pharmacokinetics and applications for inflammatory diseases. Current rheumatology reviews. 2014;10:22-34. [54] Lammers T. Smart drug delivery systems: back to the future vs. clinical reality. International journal of pharmaceutics. 2013;454:527-9. [55] Medina SH, Tekumalla V, Chevliakov MV, Shewach DS, Ensminger WD, El-Sayed ME. N-acetylgalactosamine-functionalized dendrimers as hepatic cancer cell-targeted carriers. Biomaterials. 2011;32:4118-29. [56] Prakash J, de Jong E, Post E, Gouw AS, Beljaars L, Poelstra K. A novel approach to deliver anticancer drugs to key cell types in tumors using a PDGF receptor-binding cyclic peptide containing carrier. J Control Release. 2010;145:91-101. [57] Martin CR, Preedy VR, Hunter RJ. Nanomedicine and the nervous system. 2012. [58] Arias JL. Drug targeting strategies in cancer treatment: an overview. Mini Rev Med Chem. 2011;11:1-17. [59] Toporkiewicz M, Meissner J, Matusewicz L, Czogalla A, Sikorski AF. Toward a magic or imaginary bullet? Ligands for drug targeting to cancer cells: principles, hopes, and challenges. Int J Nanomedicine. 2015;10:1399-414. [60] Trere D, Fiume L, De Giorgi LB, Di Stefano G, Migaldi M, Derenzini M. The asialoglycoprotein receptor in human hepatocellular carcinomas: its expression on proliferating cells. British journal of cancer. 1999;81:404-8. [61] Nishikawa M, Miyazaki C, Yamashita F, Takakura Y, Hashida M. Galactosylated proteins are recognized by the liver according to the surface density of galactose moieties. The American journal of physiology. 1995;268:G849-56. [62] Jayaraman N. Multivalent ligand presentation as a central concept to study intricate carbohydrate-protein interactions. Chemical Society reviews. 2009;38:3463-83. [63] Lee R, Lee Y. Enhanced biochemical affinities of multivalent neoglycoconjugates. Neoglycoconjugates: preparation and applications: Academic Press San Diego; 1994. p. 23-50. [64] Yet MG, Chin CC, Wold F. The covalent structure of individual N-linked glycopeptides from ovomucoid and asialofetuin. J Biol Chem. 1988;263:111-7. [65] Wang S, Xu H, Xu J, Zhang Y, Liu Y, Deng YH, et al. Sustained liver targeting and improved antiproliferative effect of doxorubicin liposomes modified with galactosylated lipid and PEG-lipid. AAPS PharmSciTech. 2010;11:870-7. [66] Sonoke S, Ueda T, Fujiwara K, Kuwabara K, Yano J. Galactose-modified cationic liposomes as a liver-targeting delivery system for small interfering RNA. Biol Pharm Bull. 2011;34:1338-42. [67] Alexander VM, Sano K, Yu Z, Nakajima T, Choyke PL, Ptaszek M, et al. Galactosyl Human Serum Albumin-NMP1 Conjugate: A Near Infrared (NIR)-Activatable Fluorescence Imaging Agent to Detect Peritoneal Ovarian Cancer Metastases. Bioconjugate Chemistry. 2012;23:1671-9. [68] Sun X, Hai L, Wu Y, Hu HY, Zhang ZR. Targeted gene delivery to hepatoma cells using galactosylated liposome-polycation-DNA complexes (LPD). Journal of drug targeting. 2005;13:121-8. [69] Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nature reviews Cancer. 2004;4:891-9. [70] Warburg O. On the origin of cancer cells. Science. 1956;123:309-14. [71] Stubbs M, Bashford CL, Griffiths JR. Understanding the tumor metabolic phenotype in the genomic era. Current molecular medicine. 2003;3:49-59. [72] Semenza GL. Targeting HIF-1 for cancer therapy. Nature reviews Cancer. 2003;3:721-32. [73] Volk T, Jahde E, Fortmeyer HP, Glusenkamp KH, Rajewsky MF. pH in human tumour xenografts: effect of intravenous administration of glucose. British journal of cancer. 1993;68:492-500. [74] Lee ES, Gao Z, Bae YH. Recent progress in tumor pH targeting nanotechnology. J Control Release. 2008;132:164-70. [75] Kim D, Gao ZG, Lee ES, Bae YH. In vivo evaluation of doxorubicin-loaded polymeric micelles targeting folate receptors and early endosomal pH in drug-resistant ovarian cancer. Mol Pharm. 2009;6:1353-62. [76] Fei L, Yap LP, Conti PS, Shen WC, Zaro JL. Tumor targeting of a cell penetrating peptide by fusing with a pH-sensitive histidine-glutamate co-oligopeptide. Biomaterials. 2014;35:4082-7. [77] Sun C, Shen WC, Tu J, Zaro JL. Interaction between cell-penetrating peptides and acid-sensitive anionic oligopeptides as a model for the design of targeted drug carriers. Mol Pharm. 2014;11:1583-90. [78] Sethuraman VA, Na K, Bae YH. pH-responsive sulfonamide/PEI system for tumor specific gene delivery: an in vitro study. Biomacromolecules. 2006;7:64-70. [79] Viswanathan AN, Schernhammer ES. Circulating melatonin and the risk of breast and endometrial cancer in women. Cancer Lett. 2009;281:1-7. [80] Zhou L, Yu L, Ding M, Li J, Tan H, Wang Z, et al. Synthesis and characterization of pH-sensitive biodegradable polyurethane for potential drug delivery applications. Macromolecules. 2011;44:857-64. [81] Hofmann K, Titus G, Montibeller JA, Finn FM. Avidin binding of carboxyl-substituted biotin and analogs. Biochemistry. 1982;21:978-84. [82] Doherty GJ, McMahon HT. Mechanisms of endocytosis. Annual review of biochemistry. 2009;78:857-902. [83] Rothberg KG, Heuser JE, Donzell WC, Ying YS, Glenney JR, Anderson RG. Caveolin, a protein component of caveolae membrane coats. Cell. 1992;68:673-82. [84] McMahon HT, Boucrot E. Molecular mechanism and physiological functions of clathrin-mediated endocytosis. Nature reviews Molecular cell biology. 2011;12:517-33. [85] Varkouhi AK, Scholte M, Storm G, Haisma HJ. Endosomal escape pathways for delivery of biologicals. J Control Release. 2011;151:220-8. [86] Shete HK, Prabhu RH, Patravale VB. Endosomal escape: a bottleneck in intracellular delivery. J Nanosci Nanotechnol. 2014;14:460-74. [87] Green M, Loewenstein PM. Autonomous functional domains of chemically synthesized human immunodeficiency virus tat trans-activator protein. Cell. 1988;55:1179-88. [88] Farkhani SM, Valizadeh A, Karami H, Mohammadi S, Sohrabi N, Badrzadeh F. Cell penetrating peptides: efficient vectors for delivery of nanoparticles, nanocarriers, therapeutic and diagnostic molecules. Peptides. 2014;57:78-94. [89] Milletti F. Cell-penetrating peptides: classes, origin, and current landscape. Drug Discov Today. 2012;17:850-60. [90] Rothbard JB, Garlington S, Lin Q, Kirschberg T, Kreider E, McGrane PL, et al. Conjugation of arginine oligomers to cyclosporin A facilitates topical delivery and inhibition of inflammation. Nat Med. 2000;6:1253-7. [91] Mo RH, Zaro JL, Shen WC. Comparison of cationic and amphipathic cell penetrating peptides for siRNA delivery and efficacy. Mol Pharm. 2012;9:299-309. [92] Eiriksdottir E, Mager I, Lehto T, El Andaloussi S, Langel U. Cellular internalization kinetics of (luciferin-)cell-penetrating peptide conjugates. Bioconjug Chem. 2010;21:1662-72. [93] Sayers EJ, Cleal K, Eissa NG, Watson P, Jones AT. Distal phenylalanine modification for enhancing cellular delivery of fluorophores, proteins and quantum dots by cell penetrating peptides. J Control Release. 2014;195:55-62. [94] Sethuraman VA, Bae YH. TAT peptide-based micelle system for potential active targeting of anti-cancer agents to acidic solid tumors. J Control Release. 2007;118:216-24. [95] Zaro JL, Fei L, Shen WC. Recombinant peptide constructs for targeted cell penetrating peptide-mediated delivery. J Control Release. 2012;158:357-61. [96] Jiang T, Olson ES, Nguyen QT, Roy M, Jennings PA, Tsien RY. Tumor imaging by means of proteolytic activation of cell-penetrating peptides. Proc Natl Acad Sci U S A. 2004;101:17867-72. [97] Aguilera TA, Olson ES, Timmers MM, Jiang T, Tsien RY. Systemic in vivo distribution of activatable cell penetrating peptides is superior to that of cell penetrating peptides. Integr Biol (Camb). 2009;1:371-81. [98] Olson ES, Aguilera TA, Jiang T, Ellies LG, Nguyen QT, Wong EH, et al. In vivo characterization of activatable cell penetrating peptides for targeting protease activity in cancer. Integr Biol (Camb). 2009;1:382-93. [99] Pethe K, Alonso S, Biet F, Delogu G, Brennan MJ, Locht C, et al. The heparin-binding haemagglutinin of M. tuberculosis is required for extrapulmonary dissemination. Nature. 2001;412:190-4. [100] Regino CA, Ogawa M, Alford R, Wong KJ, Kosaka N, Williams M, et al. Two-step synthesis of galactosylated human serum albumin as a targeted optical imaging agent for peritoneal carcinomatosis. Journal of medicinal chemistry. 2010;53:1579-86. [101] Knipp M, Vasak M. A colorimetric 96-well microtiter plate assay for the determination of enzymatically formed citrulline. Anal Biochem. 2000;286:257-64. [102] Qiu F, Chen YR, Liu X, Chu CY, Shen LJ, Xu J, et al. Arginine starvation impairs mitochondrial respiratory function in ASS1-deficient breast cancer cells. Science signaling. 2014;7:ra31. [103] Kasibhatla S, Amarante-Mendes GP, Finucane D, Brunner T, Bossy-Wetzel E, Green DR. Acridine Orange/Ethidium Bromide (AO/EB) Staining to Detect Apoptosis. CSH protocols. 2006;2006. [104] Wu J, Yi W, Jin L, Hu D, Song B. Antiproliferative and cell apoptosis-inducing activities of compounds from Buddleja davidii in Mgc-803 cells. Cell division. 2012;7:20. [105] Steiner DF, Hallund O, Rubenstein A, Cho S, Bayliss C. Isolation and properties of proinsulin, intermediate forms, and other minor components from crystalline bovine insulin. Diabetes. 1968;17:725-36. [106] Holtsberg FW, Ensor CM, Steiner MR, Bomalaski JS, Clark MA. Poly(ethylene glycol) (PEG) conjugated arginine deiminase: effects of PEG formulations on its pharmacological properties. J Control Release. 2002;80:259-71. [107] Wunder A, Muller-Ladner U, Stelzer EH, Funk J, Neumann E, Stehle G, et al. Albumin-based drug delivery as novel therapeutic approach for rheumatoid arthritis. Journal of immunology. 2003;170:4793-801. [108] Ge J, Neofytou E, Lei J, Beygui RE, Zare RN. Protein-polymer hybrid nanoparticles for drug delivery. Small. 2012;8:3573-8. [109] Huang YS, Chen Z, Yang ZY, Wang TY, Zhou L, Wu JB, et al. Preparation and characterization of a potent, long-lasting recombinant human serum albumin-interferon-alpha2b fusion protein expressed in Pichia pastoris. Eur J Pharm Biopharm. 2007;67:301-8. [110] Simoni A, Pellegrini M, Cecconi C, Pellegrino M. Axotomy affects density but not properties of potassium leak channels, in the leech AP neurons. Brain research. 1990;522:118-24. [111] Barnes MP, Shen WC. Disulfide and thioether linked cytochrome c-oligoarginine conjugates in HeLa cells. Int J Pharm. 2009;369:79-84. [112] Biaglow JE, Donahue J, Tuttle S, Held K, Chrestensen C, Mieyal J. A method for measuring disulfide reduction by cultured mammalian cells: relative contributions of glutathione-dependent and glutathione-independent mechanisms. Analytical biochemistry. 2000;281:77-86. [113] Chen YJ, Su JH, Tsao CY, Hung CT, Chao HH, Lin JJ, et al. Sinulariolide induced hepatocellular carcinoma apoptosis through activation of mitochondrial-related apoptotic and PERK/eIF2alpha/ATF4/CHOP pathway. Molecules. 2013;18:10146-61. [114] Zhang H, Ozaki I, Mizuta T, Hamajima H, Yasutake T, Eguchi Y, et al. Involvement of programmed cell death 4 in transforming growth factor-beta1-induced apoptosis in human hepatocellular carcinoma. Oncogene. 2006;25:6101-12. [115] Kurmyshkina O, Rapoport E, Moiseeva E, Korchagina E, Ovchinnikova T, Pazynina G, et al. Glycoprobes as a tool for the study of lectins expressed on tumor cells. Acta histochemica. 2010;112:118-26. [116] Yao Z, Zhang M, Sakahara H, Saga T, Nakamoto Y, Sato N, et al. Imaging of intraperitoneal tumors with technetium-99m GSA. Annals of nuclear medicine. 1998;12:115-8. [117] Hama Y, Urano Y, Koyama Y, Choyke PL, Kobayashi H. Targeted optical imaging of cancer cells using lectin-binding BODIPY conjugated avidin. Biochemical and biophysical research communications. 2006;348:807-13. [118] David A, Kopeckova P, Kopecek J, Rubinstein A. The role of galactose, lactose, and galactose valency in the biorecognition of N-(2-hydroxypropyl)methacrylamide copolymers by human colon adenocarcinoma cells. Pharm Res. 2002;19:1114-22. [119] Li Y, Huang G, Diakur J, Wiebe LI. Targeted delivery of macromolecular drugs: asialoglycoprotein receptor (ASGPR) expression by selected hepatoma cell lines used in antiviral drug development. Current drug delivery. 2008;5:299-302. [120] Wolf BB, Schuler M, Li W, Eggers-Sedlet B, Lee W, Tailor P, et al. Defective cytochrome c-dependent caspase activation in ovarian cancer cell lines due to diminished or absent apoptotic protease activating factor-1 activity. J Biol Chem. 2001;276:34244-51. [121] Soengas MS, Capodieci P, Polsky D, Mora J, Esteller M, Opitz-Araya X, et al. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature. 2001;409:207-11. [122] Schafer ZT, Parrish AB, Wright KM, Margolis SS, Marks JR, Deshmukh M, et al. Enhanced sensitivity to cytochrome c-induced apoptosis mediated by PHAPI in breast cancer cells. Cancer Res. 2006;66:2210-8. [123] Brizel DM, Sibley GS, Prosnitz LR, Scher RL, Dewhirst MW. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. International journal of radiation oncology, biology, physics. 1997;38:285-9. [124] Goethals L, Debucquoy A, Perneel C, Geboes K, Ectors N, De Schutter H, et al. Hypoxia in human colorectal adenocarcinoma: comparison between extrinsic and potential intrinsic hypoxia markers. International journal of radiation oncology, biology, physics. 2006;65:246-54. [125] Li XF, Carlin S, Urano M, Russell J, Ling CC, O'Donoghue JA. Visualization of hypoxia in microscopic tumors by immunofluorescent microscopy. Cancer Res. 2007;67:7646-53. [126] McAlpine JA, Lu HT, Wu KC, Knowles SK, Thomson JA. Down-regulation of argininosuccinate synthetase is associated with cisplatin resistance in hepatocellular carcinoma cell lines: implications for PEGylated arginine deiminase combination therapy. BMC cancer. 2014;14:621. [127] Tsai WB, Aiba I, Lee SY, Feun L, Savaraj N, Kuo MT. Resistance to arginine deiminase treatment in melanoma cells is associated with induced argininosuccinate synthetase expression involving c-Myc/HIF-1alpha/Sp4. Molecular cancer therapeutics. 2009;8:3223-33. [128] Changou CA, Chen YR, Xing L, Yen Y, Chuang FY, Cheng RH, et al. Arginine starvation-associated atypical cellular death involves mitochondrial dysfunction, nuclear DNA leakage, and chromatin autophagy. Proc Natl Acad Sci U S A. 2014;111:14147-52. [129] Meibohm B, Zhou H. Characterizing the impact of renal impairment on the clinical pharmacology of biologics. Journal of clinical pharmacology. 2012;52:54S-62S. [130] Choi CH, Zuckerman JE, Webster P, Davis ME. Targeting kidney mesangium by nanoparticles of defined size. Proc Natl Acad Sci U S A. 2011;108:6656-61. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/53836 | - |
dc.description.abstract | 近年來,因為蛋白質活性的專一反應和高效率使蛋白質藥物在癌症治療上的應用越來越具有前景,然而因為蛋白質的親水性和分子大小,若沒有特定的轉運蛋白或載體的幫助很難穿透細胞膜進入細胞,所以大多數應用在癌症治療上的蛋白質藥物都作用在細胞外,包括細胞膜上、血液中和腫瘤細胞外的微環境。隨著對於腫瘤生物學的了解,有更多前瞻性的蛋白質標的可以應用在癌症治療上,但受限於蛋白質對於細胞膜的穿透度低,使這些作用在細胞內的蛋白在臨床應用上有很大的限制,為了增加這些蛋白質藥物的應用性,具有腫瘤標的和胞內遞輸作用的載體的開發是很重要的一項課題。本篇研究利用兩種不同機制的策略來達到腫瘤標的性的蛋白質胞內遞送: 1. 利用標的腫瘤細胞上的受質受體誘發的胞吞作用(ligand-induced receptor mediated endocytosis);2. 利用酸鹼敏感的穿膜蛋白(pH-sensitive cell penetrating peptide)促進蛋白質在微酸性的環境下進入腫瘤細胞。 第一個部分的研究利用半乳醣化的白蛋白(galactosylated albumin)作為標的肝癌細胞的載體來運送細胞色素c (cytochrome c)。半乳糖可以被肝癌細胞上大量表現的脱唾液酸糖蛋白受體(asialoglycoprotein receptor,ASGPR)辨認,進而誘發胞吞作用把白蛋白及所攜帶的細胞色素c送進細胞內。首先,細胞實驗結果顯示,相較於未經修飾的白蛋白,半乳醣化的白蛋白顯著的提升了進入細胞內的量。接著將細胞色素c用可還原分離的雙硫鍵連結在半乳醣化的白蛋白上,使細胞色素c可以在細胞內從載體上被釋放出來。細胞吞噬實驗和毒性試驗結果顯示,利用半乳醣化白蛋白作為載體可以顯著增加細胞色素c遞送到細胞內的量,並且經由誘發細胞凋亡降低癌細胞的存活率。 第二部分的研究利用酸鹼敏感的穿膜蛋白來攜帶蛋白精氨酸脫亞氨酶(arginine deiminase,ADI)在微酸的腫瘤環境中增加胞內遞送。穿膜蛋白使用的是先前由本實驗室篩選出的HBHAc,接著利用組胺酸(histidine,H)和穀氨醯胺(glutamine,E)重複序列的短片段胜肽(HE)控制酸鹼反應性。本實驗利用蛋白質重組技術製造出帶有HBHAc和HE胜肽的蛋白精氨酸脫亞氨酶(HBHAc-HE-ADI)。利用培養在缺氧環境下的MDA-MB-231乳癌細胞作為胞內遞送及細胞毒性的體外模式。當MDA-MB-231生長在缺氧的環境下時,會誘發對蛋白精氨酸脫亞氨酶的抗藥性,同時因缺氧引起的大量醣解作用會酸化細胞培養液達到微酸性的環境。細胞實驗結果顯示,HBHAc-HE-ADI可針對缺氧酸化的細胞增加胞內遞送,同時具有酸性活化的細胞毒性,並且逆轉了缺氧誘發的抗藥性。此外,於動物實驗中發現,HBHAc-HE-ADI可利用酸鹼敏感性達到腫瘤標的作用,並達到與臨床試驗中的ADI-PEG20相同的腫瘤遞送效果。 本研究中利用兩個不同設計途徑來達到腫瘤標的性的胞內遞送。第一部分顯示利用半乳醣化的白蛋白可有效的增加細胞色素c遞送到肝癌細胞內,同時可誘發細胞凋亡而降低癌細胞存活率。第二部分利用酸鹼敏感性的穿膜蛋白將蛋白精氨酸脫亞氨酶遞送到微酸環境中的癌細胞,結果顯示其具有酸性活化的細胞毒性,同時抑制了細胞的抗藥性,並可於動物實驗中達到腫瘤標的的效果。 | zh_TW |
dc.description.abstract | The highly specific and effective action of proteins to their targets makes them a promising candidate as therapeutic agents. For the past decades, utilizing proteins therapeutics in cancer treatment became a promising method. Due to the hydrophilic nature and bulky size of proteins, they have low cell permeability without specific transporters or carriers. Therefore, most of the protein therapeutics currently under development or in clinical setting has their targets extracellularly. With the growing knowledge of cancer biology, there is more promising protein therapeutics which may target on the unbalancing molecular pathways inside of the cells. However, this category of protein therapeutics has limited clinical application. In order to improve therapeutic values of proteins acting inside of cells, carriers enhancing intracellular delivery to tumor cells are in needed. In this study, we aimed to achieve tumor targeted intracellular protein delivery through two different mechanisms: 1. ligand-induced receptor mediated endocytosis; 2. pH-sensitive cell penetrating peptide facilitated cellular internalization. For the first part of the study, we used a galactosylated albumin based carrier for intracellular delivery of cytochrome c (Cyt c) to hepatocarcinoma cells. Galactosylated albumin is recognized by highly expressed asialoglycoprotein receptors (ASGPR) on hepatocarcinoma cells and is further internalized into cells via receptor mediated endocytosis. The cell uptake study showed galactosylation significantly increase albumin internalization in a dose dependent manner. Then Cyt c was chemically conjugated to galactosylated albumin through a reducible disulfide linker in order to release Cyt c from the carrier inside of cells. We tested cellular uptake and cytotoxicity of Cyt c conjugates in ASGPR positive and negative hepatocarcinoma cells. The results showed galatosylated albumin significantly increased cellular uptake in both cell types through a galactose-related endocytic pathway, and resulting in cytotoxicity in a dose dependent manner through induction of apoptosis. For the second part of the study, we construct a pH-sensitive cell penetrating peptide (CPP) targeting the mildly acidic tumor microenvironment for intracellular delivery of arginine deiminase (ADI). The pH sensitivity of HBHAc, a CPP identified in our laboratory, was controlled by histidine-glutamine (HE)n oligopeptide. The protein constructs were generated by recombinant technology. We create a mildly acidic in vitro model by culturing MDA-MB-231 breast cancer cells in hypoxic condition. MDA-MB-231 developed ADI resistant in hypoxia. Additionally, the intensive glycolysis induced by hypoxia acidified culture media to as low as pH 6.1. The HBHAc-HE-ADI showed an increased cellular uptake and a pH activated cytotoxicity in hypoxic cultured MDA-MB-231 which restored treatment sensitivity. In addition, HBHAc-HE-ADI exhibited a comparable tumor accumulation effect to ADI-PEG20, a PEGylated ADI which is currently in clinical trials for treating different cancers. In this study, we showed two approaches for tumor targeted intracellular protein delivery. First, galactosylated albumin served as a protein drug carrier for intracellular delivery and intracellular delivery of Cyt c can be an alternative therapeutic strategy. Second, HBHAc-HE-ADI can target to mildly acidic tumor microenvironment and intracellular delivery of ADI restored hypoxia-associate resistance in MDA-MB-231. | en |
dc.description.provenance | Made available in DSpace on 2021-06-16T02:30:57Z (GMT). No. of bitstreams: 1 ntu-104-D99423005-1.pdf: 3673309 bytes, checksum: 4c5c79845f4adf310b60f4134c62939c (MD5) Previous issue date: 2015 | en |
dc.description.tableofcontents | 摘要 I Abstract III Table of Contents VI List of Schemes and Figures IX List of Tables X List of Abbreviations XI Chapter I: Introduction 1 1-1 General overview of cancer therapy 1 1-2 Hypoxia vs. malignant progression and therapy resistance 1 1-3 Applications and limitations of therapeutic proteins 3 1-3-1 Cytochorme c 4 1-3-2 Arginine deiminase (ADI) 5 1-4 Drug carriers 6 1-4-1 Albumin 6 1-5 Tumor targeted delivery 7 1-5-1 Passive targeting 8 1-5-2 Ligand-mediated targeting 9 1-5-2-1 Asialoglycoprotein receptor (ASGPR) 10 1-5-3 pH stimulated targeting 10 1-6 Intracellular delivery 12 1-6-1 Receptor mediated endocytosis (RME) 13 1-6-2 Cell penetrating peptides (CPPs) 14 1-6-2-1 HBHAc 15 Chapter II: Objectives and Aims 17 Chapter III: Materials and Methods 18 3-1 Materials 18 3-2 Cell culture 19 3-3 Preparation of BSA-GaSM 19 3-4 Preparation of Cyt c conjugates 19 3-5 Characterization of BSA-GaSM and Cyt conjugates 20 3-6 Cyt c activity assay 21 3-7 Characterization of reducible disulfide linkage 21 3-8 Expression of ASGPR in tumor cell lines 22 3-9 Cellular uptake assay of BSA, BSA-GaSM and Cyt c 22 3-10 Cell imaging by confocal microscopy 22 3-11 Tumor cell inhibition assay of Cyt c and conjugated Cyt c 23 3-12 Apoptosis assay by AO/EB double staining 23 3-13 Construct fusion protein expressing plasmids 24 3-14 Protein expression and purification 24 3-15 ADI enzyme activity assay 25 3-16 Labeling of ADI-PEG20 and ADI fusion proteins 26 3-17 Hypoxic/normoxic in vitro model 26 3-18 Cellular uptake assay of ADI-PEG20 and ADI fusion proteins 27 3-19 Cytotoxicity assay for ADI-PEG20 and ADI fusion proteins 27 3-20 Mitochondria damage assay 28 3-21 In vivo tumor accumulation imaging for ADI-PEG20 and HBHAc-HE-ADI 28 3-22 Statistics 29 Chapter IV: Results 30 4-1 Part I: Intracellular delivery of cytochrome c by galactosylated albumin 30 4-1-1 Characteristics of BSA-GaSM 30 4-1-2 ASGPR expression in hepatocarcinomas 30 4-1-3 Cellular internalization of BSA and BSA-GaSM 30 4-1-4 Characteristic of Cyt c conjugates 31 4-1-5 Reducible disulfide linkage within Cyt c and carriers 32 4-1-6 Cellular internalization of Cyt c conjugates 32 4-1-7 Cytotoxicity of Cyt c conjugates 33 4-1-8 Induction of apoptosis 34 4-1-9 Inhibition of cytotoxicity by ASF 35 4-2 Part II: Intracellular delivery of ADI by pH sensitive CPP 36 4-2-1 Hypoxia associated ADI resistant in MDA-MB-231 36 4-2-2 Construct design 36 4-2-3 Construct expression vectors 37 4-2-4 Small scale of protein expression 37 4-2-5 Large scale protein expression and purification 38 4-2-6 pH change in normoxic/hypoxic cultured cells 39 4-2-7 pH sensitive cellular uptake on normoxic/hypoxic cells 39 4-2-8 pH response cytotoxicity on normoxic/hypoxic cell model 40 4-2-9 In vivo tumor targeting effect 41 Chapter V: Discussion 43 5-1 Part I: Intracellular delivery of cytochrome c by galactosylated albumin 43 5-1-1 Material of carrier: chemical vs. natural materials 43 5-1-2 Combination of active targeting and passive targeting 43 5-1-3 Linkage type within protein drug and carrier 44 5-1-4 Inducing apoptosis in cancer therapy 45 5-1-5 ASGPR expression vs. non-expression cells 46 5-2 Part II: Intracellular delivery of ADI by pH sensitive CPP 48 5-2-1 Hypoxia-associated treatment resistance 48 5-2-2 pH dependent cellular uptake 49 5-2-3 pH and hypoxia dependent cytotoxicity 50 5-2-4. In vivo tumor targeting and elimination 51 Chapter IV: Conclusion and future prospective 54 References 88 | |
dc.language.iso | en | |
dc.title | 開發腫瘤標的性載體應用於蛋白質的胞內遞輸 | zh_TW |
dc.title | Development of Tumor Targeted Carriers for Intracellular Protein Delivery | en |
dc.type | Thesis | |
dc.date.schoolyear | 103-2 | |
dc.description.degree | 博士 | |
dc.contributor.oralexamcommittee | 江樵熹,廖嘉鴻,宋信文,林文貞,孔繁璐 | |
dc.subject.keyword | 白蛋白,細胞色素c,?唾液酸糖蛋白受體,胞內遞送,蛋白精氨酸脫亞氨?,酸鹼敏感性, | zh_TW |
dc.subject.keyword | albumin,cytochrome c,hepatocarcinoma,ASGPR,intracellular protein delivery,arginine deiminase (ADI),pH sensitive, | en |
dc.relation.page | 97 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2015-07-30 | |
dc.contributor.author-college | 藥學專業學院 | zh_TW |
dc.contributor.author-dept | 藥學研究所 | zh_TW |
顯示於系所單位: | 藥學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-104-1.pdf 目前未授權公開取用 | 3.59 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。